Aims This review summarizes the findings of preclinical studies evaluating the pleiotropic
effects of ticagrelor. These include attenuation of ischemia–reperfusion injury (IRI) …

Introduction: Ticagrelor is a first drug of a new chemical class cyclopentyltriazolopyrimidines.
It is an antiplatelet agent with a unique mechanism of action, allowing a direct and reversible …

Objective: To summarize the pharmacokinetic and pharmacodynamic properties of
ticagrelor, a selective P2Y12 receptor antagonist, and evaluate its role in the treatment of …

Ticagrelor is a P2Y12 receptor antagonist with proven clinical benefit in patients with acute
coronary syndrome. Apart from its principal antiplatelet action, pleiotropic effects have been …

Novel antiplatelet drugs, including ticagrelor, are being successively introduced into the
therapy of atherothrombotic conditions due to their superiority over a standard combination …

Ticagrelor, a novel direct and reversible P2Y12 receptor antagonist, was superior to
clopidogrel in reducing cardiovascular events among patients with acute coronary syndrome …

Background Among the 3 approved oral P2Y 12 inhibitors for the treatment for patients with
acute coronary syndrome (ACS), ticagrelor, but not prasugrel or clopidogrel, has been …

Ticagrelor is a reversible P2Y12 receptor antagonist that is more potent than clopidogrel.
When used in combination with aspirin, it reduces cardiovascular events in patients with …

Current guidelines favor dual anti-platelet therapy with ticagrelor 90 mg BID (T90BID) over
clopidogrel 75 mg QD (C75QD) in addition to aspirin for acute coronary syndrome. However …

Introduction: Dual antiplatelet therapy is a standard of care for treating patients with acute
coronary syndrome (ACS). Combination therapy with aspirin and one of the P2Y12 inhibitors …